A Phase 3 interventional study of Monofer and Iron sucrose in Chronic Kidney Disease Stage 5 (Dialysis Dependent), sponsored by Pharmacosmos A/S. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-02.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Renal Insufficiency, Chronic with a site in India — 18 open to participants now, 25 under way, 15 of them phase 3. Renal Insufficiency, Chronic · India.
Among the 64 studies in Renal Insufficiency, Chronic with a site in India, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2011, is one of 32 in phase 3, and was the 6th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →18 of the 64 studies in Renal Insufficiency, Chronic with a site in India are open now. Recruiting first, the newest first:
AstraZeneca · Sites in India, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in India, United States, Argentina and 34 more countries
Ages 18+
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18+
Eli Lilly and Company · Sites in India, Argentina, Australia and 35 more countries
Ages 50+
AstraZeneca · Sites in India, United States, Argentina and 39 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 32 · Phase 4 5
First in 2007; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 351 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 570 across the 54 interventional studies, 904 across the 10 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
Pharmacosmos A/S has 6 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Renal Insufficiency, Chronic with a site in India that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06763146BayerAn Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | 2026-11-30 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Renal Insufficiency, Chronic with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a diagnosis of CKD-5D, in dialysis therapy for at least 90 days prior to inclusion, will be included if they meet all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
Drug: Monofer
Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
Drug: Iron sucrose
Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
Ability to Maintain Hemoglobin Level
The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6. Haemoglobin was measured by a blood sample at the different visits. All blood samples were taken before the dialysis from the dialysis catheter. Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.
Time frame: Baseline to 6 weeks
Change in Hemoglobin Concentration
Time frame: 6 weeks
| Milestone | Iron Isomaltoside 1000 | Iron Sucrose |
|---|---|---|
| Started | 234 | 117 |
| Completed | 210 | 113 |
| Not completed | 24 | 4 |
The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6. Haemoglobin was measured by a blood sample at the different visits. All blood samples were taken before the dialysis from the dialysis catheter. Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.
| percentage of participants | Iron Isomaltoside 1000 | Iron Sucrose |
|---|---|---|
| Ability to Maintain Hemoglobin Level | 82.7 | 82.6 |
| g/dL | Iron Isomaltoside 1000 | Iron Sucrose |
|---|---|---|
| Change in Hemoglobin Concentration | -0.07 (-5.5 to 2.9) | -0.06 (-4.9 to 2.8) |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside 1000 | — | 22/230 (9.6%) | 42/230 (18.3%) |
| Iron Sucrose | — | 6/114 (5.3%) | 16/114 (14%) |
| Event | Iron Isomaltoside 1000 | Iron Sucrose |
|---|---|---|
| fallInjury, poisoning and procedural complications | 3/230 | 0/114 |
| lower respiratory tract infectionInfections and infestations | 1/230 | 1/114 |
| staphylococcol bacteraimiaInfections and infestations | 0/230 | 1/114 |
| anaesthetic complicationInjury, poisoning and procedural complications | 0/230 | 1/114 |
| road traffic accidentInjury, poisoning and procedural complications | 0/230 | 1/114 |
| prostatitisReproductive system and breast disorders | 0/230 | 1/114 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 0/230 | 1/114 |
| arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications | 2/230 | 0/114 |
| acute coronary syndromeCardiac disorders | 1/230 | 0/114 |
| acute myocardial infarctionCardiac disorders | 1/230 | 0/114 |
| Event | Iron Isomaltoside 1000 | Iron Sucrose |
|---|---|---|
| hyperphosphataemiaMetabolism and nutrition disorders | 5/230 | 4/114 |
| headacheNervous system disorders | 7/230 | 4/114 |
| fallInjury, poisoning and procedural complications | 7/230 | 0/114 |
| lower respiratory tract infectionInfections and infestations | 4/230 | 3/114 |
| nasopharyngitisInfections and infestations | 6/230 | 1/114 |
| C-reactive protein increasedInvestigations | 6/230 | 1/114 |
| diarrhoeaGastrointestinal disorders | 5/230 | 2/114 |
| procedural hypotensionInjury, poisoning and procedural complications | 5/230 | 1/114 |
| pain in extremityMusculoskeletal and connective tissue disorders | 5/230 | 0/114 |
| Age, Categorical(Participants) | Iron Isomaltoside 1000 | Iron Sucrose | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 129 | 66 | 195 |
| >=65 years | 105 | 51 | 156 |
| Age, Continuous(years) | Iron Isomaltoside 1000 | Iron Sucrose | Total |
|---|---|---|---|
| Mean | 60.2 ± 16.2 | 59.5 ± 15.4 | 60.0 ± 15.9 |
| Sex: Female, Male(Participants) | Iron Isomaltoside 1000 | Iron Sucrose | Total |
|---|---|---|---|
| Female | 76 | 43 | 119 |
| Male | 158 | 74 | 232 |
| Region of Enrollment(participants) | Iron Isomaltoside 1000 | Iron Sucrose | Total |
|---|---|---|---|
| India | 44 | 28 | 72 |
| United Kingdom | 131 | 56 | 187 |
| Russian Federation | 6 | 3 | 9 |
| Poland | 10 | 3 | 13 |
| Sweden | 6 | 4 | 10 |
| Switzerland | 13 | 6 | 19 |
| Romania | 14 | 12 | 26 |
| Denmark | 6 | 5 | 11 |
| United States | 4 | 0 | 4 |
The record gives a start of Jun 2011, a primary completion of Oct 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iron isomaltoside 1000 · Iron sucrose
Renal Insufficiency, Chronic →